SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.

C, Rochlitz; M, Bigler; Moos R, von; J, Bernhard; K, Matter-Walstra; A, Wicki; K, Zaman; S, Anchisi; M, Küng; KJ, Na; D, Bärtschi; M, Borner; T, Rordorf; D, Rauch; A, Müller; T, Ruhstaller; M, Vetter; A, Trojan; U, Hasler-Strub; R, Cathomas; R, Winterhalder

doi:10.1186/s12885-016-2823-y

Public

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.

Shared by NobleBlocks on Oct 10, 2016 • 12:00 AM UTC

Authors:

Rochlitz C

Bigler M

von Moos R

Abstract

<h4>Background</h4>Adding bevacizumab to chemotherapy improves response rates and progression-free survival (PFS) in metastatic breast cancer (mBC). We aimed to demonstrate decreased toxicity with metronomic chemotherapy/bevacizumab compared with paclitaxel/bevacizumab.<h4>Methods</h4>This multicent...

Subject

Toxicity

Breast cancer

Bevacizumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!